Drugs / ASP5094
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02698657 | Feb 2016 → Sep 2017 | rheumatoid arthritis | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03257852 | Sep 2017 → Sep 2018 | rheumatoid arthritis | Astellas Pharma Inc | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP5094 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03257852 ↗ |
| Action | Inhibit | “ASP5094 was designed to inhibit human α9” PMID 33087159 ↗ Oct 2020 |
| Modality | Monoclonal antibody | “The humanized immunoglobulin G1 monoclonal antibody ASP5094” PMID 33087159 ↗ Oct 2020 |